Terms: = Breast cancer AND HNF1A, HNF1, 6927, ENSG00000135100, TCF1, MODY3, P20823, LFB1 AND Prognosis
2 results:
1. Distinct profiles of proliferating CD8+/tcf1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
[TBL] [Abstract] [Full Text] [Related]
2. Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis.
Hassing CMS; Nielsen DL; Knoop AS; Tvedskov THF; Kroman N; Lænkholm AV; Juhl CB; Kümler I
Crit Rev Oncol Hematol; 2023 Apr; 184():103952. PubMed ID: 36854373
[TBL] [Abstract] [Full Text] [Related]
